Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Approaches to integrating germline and tumor genomic data in cancer research.
Feigelson HS, Goddard KA, Hollombe C, Tingle SR, Gillanders EM, Mechanic LE, Nelson SA. Feigelson HS, et al. Among authors: goddard ka. Carcinogenesis. 2014 Oct;35(10):2157-63. doi: 10.1093/carcin/bgu165. Epub 2014 Aug 12. Carcinogenesis. 2014. PMID: 25115441 Free PMC article. Review.
Cancer Health Assessments Reaching Many (CHARM): A clinical trial assessing a multimodal cancer genetics services delivery program and its impact on diverse populations.
Mittendorf KF, Kauffman TL, Amendola LM, Anderson KP, Biesecker BB, Dorschner MO, Duenas DM, Eubanks DJ, Feigelson HS, Gilmore MJ, Hunter JE, Joseph G, Kraft SA, Lee SSJ, Leo MC, Liles EG, Lindberg NM, Muessig KR, Okuyama S, Porter KM, Riddle LS, Rolf BA, Rope AF, Zepp JM, Jarvik GP, Wilfond BS, Goddard KAB; CHARM study team. Mittendorf KF, et al. Contemp Clin Trials. 2021 Jul;106:106432. doi: 10.1016/j.cct.2021.106432. Epub 2021 May 11. Contemp Clin Trials. 2021. PMID: 33984519 Free PMC article. Clinical Trial.
Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access.
Amendola LM, Shuster E, Leo MC, Dorschner MO, Rolf BA, Shirts BH, Gilmore MJ, Okuyama S, Zepp JM, Kauffman TL, Mittendorf KF, Bellcross C, Jenkins CL, Joseph G, Riddle L, Syngal S, Ukaegbu C, Goddard KAB, Wilfond BS, Jarvik GP; CHARM Study. Amendola LM, et al. Genet Med. 2022 Jun;24(6):1196-1205. doi: 10.1016/j.gim.2022.02.006. Epub 2022 Mar 16. Genet Med. 2022. PMID: 35305866 Free article.
Adaptation and early implementation of the PREdiction model for gene mutations (PREMM5™) for lynch syndrome risk assessment in a diverse population.
Mittendorf KF, Ukaegbu C, Gilmore MJ, Lindberg NM, Kauffman TL, Eubanks DJ, Shuster E, Allen J, McMullen C, Feigelson HS, Anderson KP, Leo MC, Hunter JE, Sasaki SO, Zepp JM, Syngal S, Wilfond BS, Goddard KAB. Mittendorf KF, et al. Fam Cancer. 2022 Apr;21(2):167-180. doi: 10.1007/s10689-021-00243-3. Epub 2021 Mar 23. Fam Cancer. 2022. PMID: 33754278 Free PMC article.
KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.
Webster J, Kauffman TL, Feigelson HS, Pawloski PA, Onitilo AA, Potosky AL, Cross D, Meier PR, Mirabedi AS, Delate T, Daida Y, Williams AE, Alexander GL, McCarty CA, Honda S, Kushi LH, Goddard KA; CERGEN study team. Webster J, et al. Among authors: goddard ka. Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):91-101. doi: 10.1158/1055-9965.EPI-12-0545. Epub 2012 Nov 15. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 23155138 Free PMC article.
169 results